Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Patient-centric trials for therapeutic development in precision oncology.

Literature DB >> 26469047

Patient-centric trials for therapeutic development in precision oncology.

Andrew V Biankin^1,2,3,4, Steven Piantadosi⁵, Simon J Hollingsworth⁶.

Abstract

An enhanced understanding of the molecular pathology of disease gained from genomic studies is facilitating the development of treatments that target discrete molecular subclasses of tumours. Considerable associated challenges include how to advance and implement targeted drug-development strategies. Precision medicine centres on delivering the most appropriate therapy to a patient on the basis of clinical and molecular features of their disease. The development of therapeutic agents that target molecular mechanisms is driving innovation in clinical-trial strategies. Although progress has been made, modifications to existing core paradigms in oncology drug development will be required to realize fully the promise of precision medicine.

Entities: Disease Species

Mesh：

Year: 2015 PMID： 26469047 DOI： 10.1038/nature15819

Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962

55 in total

1. Failure rate: Why many cancer drugs don't receive FDA approval, and what can be done about it.

Authors: Carrie Printz
Journal: Cancer Date: 2015-05-15 Impact factor: 6.860

2. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors: Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal: N Engl J Med Date: 2010-06-24 Impact factor: 91.245

Review 3. Clinical trial designs for predictive marker validation in cancer treatment trials.

Authors: Daniel J Sargent; Barbara A Conley; Carmen Allegra; Laurence Collette
Journal: J Clin Oncol Date: 2005-03-20 Impact factor: 44.544

Review 4. Implementing personalized cancer genomics in clinical trials.

Authors: Richard Simon; Sameek Roychowdhury
Journal: Nat Rev Drug Discov Date: 2013-05 Impact factor: 84.694

5. Adjuvant trastuzumab in HER2-positive breast cancer.

Authors: Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal: N Engl J Med Date: 2011-10-06 Impact factor: 91.245

6. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors: Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal: N Engl J Med Date: 2012-02-23 Impact factor: 91.245

Review 7. Cancer genomics: the challenge of drug accessibility.

Authors: Jeremy Lewin; Lillian L Siu
Journal: Curr Opin Oncol Date: 2015-05 Impact factor: 3.645

8. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial.

Authors: Alda L Tam; Edward S Kim; J Jack Lee; Joe E Ensor; Marshall E Hicks; Ximing Tang; George R Blumenschein; Christine M Alden; Jeremy J Erasmus; Anne Tsao; Scott M Lippman; Waun K Hong; Ignacio I Wistuba; Sanjay Gupta
Journal: J Thorac Oncol Date: 2013-04 Impact factor: 15.609

9. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.

Authors: Apostolia-Maria Tsimberidou; Nancy G Iskander; David S Hong; Jennifer J Wheler; Gerald S Falchook; Siqing Fu; Sarina Piha-Paul; Aung Naing; Filip Janku; Rajyalakshmi Luthra; Yang Ye; Sijin Wen; Donald Berry; Razelle Kurzrock
Journal: Clin Cancer Res Date: 2012-09-10 Impact factor: 12.531

10. An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.

Authors: Laetitia Seguin; Shumei Kato; Aleksandra Franovic; M Fernanda Camargo; Jacqueline Lesperance; Kathryn C Elliott; Mayra Yebra; Ainhoa Mielgo; Andrew M Lowy; Hatim Husain; Tina Cascone; Lixia Diao; Jing Wang; Ignacio I Wistuba; John V Heymach; Scott M Lippman; Jay S Desgrosellier; Sudarshan Anand; Sara M Weis; David A Cheresh
Journal: Nat Cell Biol Date: 2014-04-20 Impact factor: 28.824

87 in total

1. Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer.

Authors: Sejin Chung; Paris Vail; Agnieszka K Witkiewicz; Erik S Knudsen
Journal: Clin Cancer Res Date: 2018-12-11 Impact factor: 12.531

2. Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials.

Authors: Seung Tae Kim; Kyoung-Mee Kim; Nayoung K D Kim; Joon Oh Park; Soomin Ahn; Jae-Won Yun; Kyu-Tae Kim; Se Hoon Park; Peter J Park; Hee Cheol Kim; Tae Sung Sohn; Dong Il Choi; Jong Ho Cho; Jin Seok Heo; Wooil Kwon; Hyuk Lee; Byung-Hoon Min; Sung No Hong; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Woong-Yang Park; Jeeyun Lee
Journal: Oncologist Date: 2017-07-12

Patient-centric trials for therapeutic development in precision oncology.

1. Failure rate: Why many cancer drugs don't receive FDA approval, and what can be done about it.

2. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Review 3. Clinical trial designs for predictive marker validation in cancer treatment trials.

Review 4. Implementing personalized cancer genomics in clinical trials.

5. Adjuvant trastuzumab in HER2-positive breast cancer.

6. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Review 7. Cancer genomics: the challenge of drug accessibility.

8. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial.

9. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.

10. An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.

1. Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer.

2. Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials.

Review 3. The impact of structural biology in medicine illustrated with four case studies.

4. Debunking the Delusion That Precision Oncology Is an Illusion.

5. Nuclear Medicine in the Era of Precision Medicine.

6. Glomerular disease: Personalized immunomonitoring in lupus and lupus nephritis.

Review 7. Personalized Cancer Models for Target Discovery and Precision Medicine.

Review 8. Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality.

9. Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer.

Review 10. The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.